Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need
| Autor: | Andrew D. Cox, Chantelle M. Cairns, Wei Zou, Mélanie Arbour, Evgeny Vinogradov, Luke Masson, Perry Fleming, Frank St. Michael, Dean Williams |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Bacterial capsule Serotype Canada Haemophilus Infections Glycoconjugate Disease Biology medicine.disease_cause Haemophilus influenzae serotype a Microbiology Haemophilus influenzae 03 medical and health sciences Mice 0302 clinical medicine Conjugate vaccine medicine Animals Humans 030212 general & internal medicine Serotyping Pathogen Bacterial Capsules Haemophilus Vaccines chemistry.chemical_classification Mice Inbred BALB C General Veterinary General Immunology and Microbiology Polysaccharides Bacterial Vaccination Public Health Environmental and Occupational Health Virology capsular polysaccharide 030104 developmental biology Infectious Diseases chemistry conjugate vaccine Molecular Medicine Female Public Health Rabbits Glycoconjugates Alaska |
| Zdroj: | Vaccine. 35(45) |
| ISSN: | 1873-2518 |
| Popis: | After the introduction of the glycoconjugate vaccine based upon the capsular polysaccharide of Haemophilus influenzae type b in the mid 1980s there was a remarkable decrease in the number of invasive cases reported for this organism. Since the 1990s several groups have observed the emergence of Haemophilus influenzae type a (Hia), especially in indigenous communities in the northern regions of Canada and Alaska, to a stage where a solution is warranted to prevent further unnecessary deaths due to this pathogen. A glycoconjugate vaccine solution based upon the type a capsular polysaccharide (CPS) was investigated pre-clinically in an effort to illustrate the proof of concept for this approach. In this study we describe the growth of Hia and the isolation, purification and conjugation of the CPS to several carrier proteins. The resulting glycoconjugates were immunised in mice and rabbits provoking sera that facilitated bactericidal killing against all type a strains that we tested. This study has illustrated the pre-clinical proof of concept of a glycoconjugate vaccine based on the CPS of Hia as a solution to this emerging disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect